Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew L Frelinger

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Plos One|June 25, 2025
Association of microtubule destabilization with platelet yields in terminally differentiating hiPSC-derived megakaryocyte linesEmiri Nakamura, Yasuo Harada, Trevor Bingham, et al.
Biomedical Microdevices|July 29, 2016
Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endotheliumAbhishek Jain, Andries D van der Meer, Anne-Laure Papa, et al.
Journal of Thrombosis and Thrombolysis|July 20, 2020
Biomarkers of platelet activation and cardiovascular risk in the DAPT trialDavid D Berg, Robert W Yeh, Laura Mauri, et al.
European Heart Journal|May 14, 2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trialAlan D Michelson, Andrew L Frelinger, Eugene Braunwald, et al.
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Research and Practice in Thrombosis and Haemostasis|April 22, 2026
The association between immature platelet count and clinical characteristics in pediatric immune thrombocytopeniaEmily M Harris, Michele P Lambert, Amanda Grimes, et al.
Scientific Reports|May 15, 2024
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndromeAndrew L Frelinger, Robin L Haynes, Richard D Goldstein, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Plos One|June 25, 2025
Association of microtubule destabilization with platelet yields in terminally differentiating hiPSC-derived megakaryocyte linesEmiri Nakamura, Yasuo Harada, Trevor Bingham, et al.
Biomedical Microdevices|July 29, 2016
Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endotheliumAbhishek Jain, Andries D van der Meer, Anne-Laure Papa, et al.
Journal of Thrombosis and Thrombolysis|July 20, 2020
Biomarkers of platelet activation and cardiovascular risk in the DAPT trialDavid D Berg, Robert W Yeh, Laura Mauri, et al.
European Heart Journal|May 14, 2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trialAlan D Michelson, Andrew L Frelinger, Eugene Braunwald, et al.
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Research and Practice in Thrombosis and Haemostasis|April 22, 2026
The association between immature platelet count and clinical characteristics in pediatric immune thrombocytopeniaEmily M Harris, Michele P Lambert, Amanda Grimes, et al.
Scientific Reports|May 15, 2024
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndromeAndrew L Frelinger, Robin L Haynes, Richard D Goldstein, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 10